USA Today: Paxlovid, Pfizer’s COVID pill, showed no measurable benefit in adults 40 to 65, study says
According to a large new Israeli study Pfizer’s CVOID-19 pills are hardly effective in younger adults ages 40 to 65. The data is clear that for the elderly past the age of 65 the pill reduces risk of hospitalization by 65% but such results were not replicated in younger adults. This new research puts in doubt the Biden Administration’s decision to spend more than $10 billion on purchasing the pill due to its at-home convenience and perceived effectiveness for all age groups. A Pfizer spokesperson declined to speak on these findings but a response from the company should be made public in the coming days. The full article by Matthew Perrone can be read here on USA Today. For more information on COVID-19 click here.